GlaxoSmithKline Plc has announced that its investigational immunotherapy for melanoma that targets the MAGE-A3 antigen, did not meet its first co-primary endpoint in a Phase 3 study of patients with the disease. ---Subscribe to MedNous to access this article--- Clinical Research Company News
